Evidence map›Paper›PMID 41410902›Full record

ArticleJournal of neuro-oncology2025

Combined stereotactic radiotherapy and immunotherapy improves survival in driver-gene-negative NSCLC patients with brain oligo-metastases: a multicenter real-world study.

Shilan Luo, Rufei Liu, Peng Li, Hongbin Tu, Shuangqing Lu, Jingdan Pang, Lu Meng, Litang Huang, Yingying Wang, Dawei Chen and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shilan Luo *Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Rufei Liu *Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Peng Li *Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Hongbin Tu *Department of Integrated TCM & Western Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Shuangqing LuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jingdan PangDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Lu MengDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Litang HuangDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Yingying WangDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Dawei ChenShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. dave0505@yeah.net.
Xiaomei GongDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. gongxiaomei1981@163.com.ORCID http://orcid.org/0000-0002-3043-9562

Funding

Clinical Research Foundation of Shanghai Pulmonary Hospital SKPY2021006National Natural Science Foundation of China 82473378Shanghai Municipal Health Commission Seed Funding Program for Research and Translation of New Medical Technologies 2025ZZ2011Shanghai Talents Development Fund Project 2021071the Shanghai Pulmonary Hospital Research-Oriented Physician Talent Program LYRC202407Tongji University Medicine-X Interdisciplinary Research Initiative TJ-FK-YXJC022
6 · The paper itself

Abstract

purposeThis study evaluates the efficacy and safety of combining stereotactic radiotherapy (SRT) with immune checkpoint inhibitors (ICIs) and chemotherapy (ChT) for treating brain oligo-metastases (BMs) in driver-gene-negative non-small cell lung cancer (NSCLC).

methodsIn this retrospective multi-center study, 255 NSCLC patients with 1–3 BMs were categorized into three groups: SRT + ICIs + ChT (n = 100), SRT + ChT (n = 76), and ICIs + ChT (n = 79). Outcomes included overall survival (OS), intracranial progression-free survival (iPFS), progression-free survival (PFS), and intracranial objective response rate (iORR). Propensity score generation and 1:1:1 matching of patients were performed based on the nine covariates for their potential association with survival outcomes.

resultsIn the propensity score-matched cohort (n = 207), the SRT + ICIs + ChT group demonstrated significantly superior iORR (55.2% vs. 32.9%/49.4%, p = 0.012) and survival outcomes (median OS: 24.7 vs. 14.7/17.8 months, p = 0.028; iPFS: 17.0 vs. 7.8/13.0 months, p = 0.0014) compared to SRT + ChT and ICIs + ChT groups. For BMs ≥ 0.5 cm³, SRT + ICIs + ChT demonstrated superior OS (25.3 vs. 13.5/18.5 months; p < 0.001), iPFS (18.0 vs. 7.8/11.8 months; p < 0.001), PFS (13.1 vs. 7.4/7.1 months; p < 0.001), and iORR (57.0% vs. 31.7%/35.1%; p = 0.006) compared to SRT + ChT or ICIs + ChT. Symptomatic BM subgroups showed similar trends (OS: 24.7 vs. 14.5/17.1 months; p = 0.003). In patients receiving SRT combined with ICIs and ChT, concurrent therapy (within both 2-week and 4-week interval) demonstrated significantly superior outcomes over sequential therapy, including prolonged OS (31.6 vs. 17.2–17.7 months), iPFS, and PFS, as well as higher iORR (66.1%/67.2% vs. 39.10%/35.6%) and iDCR. No increased incidence of CNS or immune-related adverse events was observed with combination therapy.

conclusionsConcurrent SRT-ICI-ChT synergistically enhances survival and intracranial control in driver-gene-negative NSCLC patients with BMs, particularly for symptomatic or larger lesions (≥ 0.5 cm³), without elevating toxicity risks. These findings advocate for integrated radiosurgery-immunotherapy approaches in managing NSCLC brain metastases.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsRadiosurgeryAdultAgedAged, 80 and overCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisImmune Checkpoint InhibitorsBrain metastasesImmune checkpoint inhibitorsNon-small cell lung cancerStereotactic radiotherapy

Identifiers

PMID41410902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.